Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis
- 26 October 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Pain
- Vol. 160 (2) , 486-492
Abstract
Joint inflammation is present in a subpopulation of knee osteoarthritis (OA) patients. Proinflammatory cytokines are known to sensitize the peripheral and central pain pathways. This can be mechanistically assessed by pressure pain thresholds and temporal summation of pain (TSP). Nonsteroidal anti-inflammatory drugs (NSAIDs) combined with paracetamol are recommended as OA treatment. The current study hypothesized that evidence of central sensitization would predict poor responses to peripherally directed therapies in knee OA and therefore aimed to investigate the value of mechanistic pain profiling for predicting pain outcome of treatment with NSAIDs plus paracetamol. One hundred thirty-two patients received ibuprofen 1200 mg/daily, paracetamol 3 g/daily, and pantoprazole 20 mg/daily for 3 weeks. Before administration, cuff pain detection, tolerance threshold, and TSP were assessed. Worst pain within the last 24 hours and pain during activity (visual analogue scales) were assessed before and after treatment. Facilitated TSP was found at baseline in the nonresponders to the 3-weeks treatment as compared to responders for both the 30% and 50% pain alleviation criteria (P < 0.02). Linear regression models identified facilitated TSP (P < 0.01) and low clinical pain scores (P < 0.001) as independent factors for prediction of poor pain alleviation by the treatment. In conclusion, this study found that mechanistic pain profiling can predict pain alleviation of NSAIDs and paracetamol. Facilitated TSP and low clinical pain scores before treatment are independent predictors of poor pain alleviation after NSAIDs and paracetamol. This study adds to the growing evidence that a subgroup of knee OA patients with manifested central sensitization may require special management attention.Keywords
This publication has 59 references indexed in Scilit:
- Assessment and manifestation of central sensitisation across different chronic pain conditionsEuropean journal of pain, 2017
- Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly VolunteersClinical Drug Investigation, 2017
- Joint pain: more to it than just structural damage?Pain, 2017
- Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritisPain, 2016
- A mechanism‐based pain sensitivity index to characterize knee osteoarthritis patients with different disease stages and pain levelsEuropean journal of pain, 2014
- Sensitization in patients with painful knee osteoarthritisPain, 2010
- Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluationHealth Technology Assessment, 2008
- Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociceptionPain, 2007
- Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trialsBMJ, 2004
- Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid.British Journal of Clinical Pharmacology, 1995